Cytosorbents Corporation

Overview

<section> <heading>How the company got here</heading> <body_content> Cytosorbents Corporation, founded in 1997, has evolved from its previous identity as MedaSorb Technologies Corporation, a name change occurring in May 2010. The company's core focus is on developing and commercializing medical devices that utilize blood purification technology. A significant turning point was the CE mark approval of its flagship product, CytoSorb, in 2011, which allowed for its sale in the European Union. This marked the beginning of its international presence and the establishment of its blood purification platform. The company has since secured substantial funding through grants and contracts from various U.S. government agencies, including DARPA and the U.S. Army, to further its research and development in critical care technologies. </body_content> </section> <section> <heading>What it actually does</heading> <body_content> Cytosorbents Corporation develops and sells medical devices that purify blood. Think of it like a specialized filter for the bloodstream. Their main technology uses tiny, porous polymer beads, which act like sponges to soak up harmful substances from the blood. This process, called hemoadsorption, is used in critical care situations to help remove things like excess inflammatory substances, toxins, or certain drugs that can cause serious health problems. These devices are designed to be used in hospitals, connected to machines that circulate a patient's blood outside their body for filtering before returning it. </body_content> </section> <section> <heading>CytoSorb</heading> <body_content> CytoSorb is the company's primary product and represents its main source of revenue. It's a blood purification cartridge designed to remove harmful substances, such as cytokines (which can cause widespread inflammation, known as a "cytokine storm"), bilirubin (a waste product from the liver), and myoglobin (a protein released from damaged muscles) from the blood. It's also used to remove certain blood-thinning medications during and after heart surgery to reduce bleeding risks. CytoSorb has received approval in the European Union and is used in many countries worldwide, making it the company's most established business line. </body_content> </section> <section> <heading>DrugSorb-ATR</heading> <body_content> DrugSorb-ATR is an investigational device that the company is developing, particularly for use in the United States and Canada. Its purpose is to remove blood-thinning drugs (anticoagulants) from the blood, specifically in patients undergoing high-risk surgeries like heart bypass surgery. The goal is to reduce the risk of severe bleeding during and after these procedures. While it has received "Breakthrough Device Designation" from the FDA, it is not yet approved for sale in the U.S. or Canada, and the company is working through the regulatory process. </body_content> </section> <section> <heading>VetResQ</heading> <body_content> VetResQ is a blood purification adsorber specifically designed for veterinary use in animals. It functions similarly to CytoSorb, using porous polymer beads to remove toxins and inflammatory substances from an animal's blood. This product is intended to treat critical conditions in animals, such as sepsis (a severe response to infection), poisoning, and severe inflammation. It's available in different sizes to accommodate various animal species and is compatible with standard veterinary blood-filtering machines. </body_content> </section> <section> <heading>PuriFi</heading> <body_content> PuriFi is a specialized blood pump designed to work with Cytosorbents' blood purification cartridges, like CytoSorb. It's essentially a piece of equipment that helps move the blood through the purification device. The PuriFi pump is designed to be user-friendly, with features like an intuitive touchscreen and quick setup, making it easier for medical staff to administer blood purification therapies. Its launch in the European Union is intended to complement the use of CytoSorb and potentially increase its adoption. </body_content> </section> <section> <heading>HemoDefend-BGA</heading> <body_content> HemoDefend-BGA is a blood purification technology platform that the company is developing. Its specific function is to remove anti-A and anti-B antibodies from plasma and whole blood. This technology is aimed at enabling the creation of "universal" blood products, meaning blood that can be transfused to recipients regardless of their blood type. This could significantly simplify blood transfusions, especially in emergency situations or on the battlefield, by reducing the need for precise blood type matching. </body_content> </section> <section> <heading>What management is betting on now</heading> <body_content> Cytosorbents' management is focused on expanding the reach and application of its blood purification technology. A key strategy is gaining regulatory approval in the United States for its DrugSorb-ATR system, which addresses a critical need for managing bleeding risks in cardiac surgery patients. They are also working to increase the adoption of their existing CytoSorb product in Europe and other international markets, supported by the launch of their PuriFi pump to facilitate easier use. Furthermore, continued development and potential commercialization of other technologies like HemoDefend-BGA for universal blood products represent long-term growth opportunities. </body_content> </section>